Editorial

A newly discovered role of metabolic enzyme PCK1 as a protein kinase to promote cancer lipogenesis

Lipid metabolism, in particular fatty acid and cholesterol synthesis, is essential to convert nutrients into metabolic intermediates for membrane biosynthesis, energy storage and the generation of signaling molecules. Tumor cells maintain high level of lipid metabolism for rapid cell proliferation [1-4]. Transcription of genes required for fatty acid and cholesterol synthesis and cholesterol uptake is controlled by membrane-bound transcription factor sterol regulatory element-binding proteins (SREBPs), including SREBP-1a, SREBP-1c/ADD1 and SREBP-2 isoforms [5]. The function of SREBPs is mainly regulated by an escort protein (the SREBP cleavage-activating protein [SCAP]) and endoplasmic reticulum (ER) anchor proteins (insulin-induced genes [Insigs]), during the feedback loop of cholesterol synthesis [6-8]. Under sterol-depleted conditions, SCAP and SREBPs complex is captured by COPII-mediated vesicles and transported from the ER to the Golgi apparatus [7, 9], where the SREBPs are proteolytically processed by Site-1 protease (S1P) and Site-2 protease (S2P) to yield active amino-terminal fragments that enter the nucleus for gene transcription [10, 11]. Under high intracellular sterol conditions, abundant cholesterol in the ER membrane binds to SCAP, induces its conformational change, and enables it to bind to Insigs. When SCAP interacts with Insigs, COPII proteins can no longer bind to a hexapeptide sorting signal (MELADL) in SCAP, leading to the retention of the SREBP-SCAP complex in the ER [6, 12, 13].

Two Insig isoforms, Insig1 (277 amino acids) and Insig2 (225 amino acids, sharing 69% amino acid identity with Insig1), contain 6 transmembrane-spanning regions and differ in their cytosolic N-termini [14, 15]. Insig proteins do not bind to cholesterol. Instead, they bind to oxysterols, which are cholesterol derivatives-including 22-, 24-, 25-, and 27-hydroxycholesterol, in the central cavities within their transmembrane domains. Insigs interact with SCAP via transmembrane domains 3 and 4 [6, 16-18]. The binding of oxysterols to Insigs is crucial for the interaction between Insigs and SCAP, which does not bind to oxysterols [9, 17, 18]. Thus, cholesterol and oxysterols block COPII binding to SCAP by binding to different intracellular receptors, cholesterol to SCAP and oxysterols to Insigs. Similar to the effect of cholesterol deprivation, low oxysterol conditions disrupt the Insigs-SCAP interaction, leading to SREBP activation and concomitant Insig ubiquitination and degradation [9, 17-19]. In addition to its function to hinder the ER-to-Golgi transport of the SREBP-SCAP complex, Insigs promote the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), thereby reducing cholesterol synthesis [10]. Although it is well known that the interaction between Insigs and the SREBP-SCAP complex is regulated by intracellular sterol levels, whether the binding of oxysterol to Insigs is regulated without alteration of oxysterol levels for SREBP activation in response to oncogenic signaling remains elusive.

Cancer cells favor glycolysis to provide energy and metabolic intermediates for synthesis lipids, proteins, and nucleic acids regardless of the presence or absence of oxygen, and this phenomenon is referred to as the Warburg effect [20, 21]. Gluconeogenesis, which in essence is the reverse pathway of glycolysis that results in the generation of glucose from certain non-carbohydrate carbon substrates, is in principle suppressed in cancer cells with highly activated glycolysis [20]. Consistently,

Abbreviations: ACC1, acetyl-CoA carboxylase-1; AKT1ISI, AKT1 substrate 1; ChiP, ChiP-interacting protein; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; FASN, fatty acid synthase; GPAT, glycerol-3-phosphate acyltransferase; HCC, hepatocellular carcinoma; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HMGCS, HMGCo synthase; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; Insig, insulin-induced gene; KHK-A, ketohexokinase-A; LDLR, low-density lipoprotein receptor; MLC2, myosin light chain 2; PCK1, phosphoenolpyruvate carboxykinase 1; PGF, platelet-derived growth factor; PDHKL1, pyruvate dehydrogenase kinase 1; PEP, phosphoenolpyruvate; PGK1, phosphoglycerate kinase 1; PKM2, pyruvate kinase M2; PRPS1, phosphoribosylpyrophosphate synthetase 1; S1P, site-1 protease; S2P, site-2 protease; SCAP, SREBP cleavage-activating pro–tein; SCD1, stearoyl-CoA desaturase-1; SNAP-23, synaptosome-associated protein 23; SREBP, sterol regulatory element-binding protein; SS, squalene synthase

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center
forced expression of phosphoenolpyruvate carboxykinase (PCK or PEPCK), which has a cytoplasmic phosphoenolpyruvate carboxykinase 1 (PCK1) and a mitochondrial PCK2 isoforms and is a rate-limiting enzyme of gluconeogenesis that converts oxaloacetate and GTP into phosphoenolpyruvate (PEP) and CO2 by addition of coneogenesis that converts oxaloacetate and GTP into PCK2 isoforms and is a rate-limiting enzyme of gluconeogenesis that converts oxaloacetate and GTP into phosphoenolpyruvate carboxykinase 2 (PCK2), which has a cytoplasmic phosphoenolpyruvate carboxykinase 2 (PCK2). However, upregulated expression of PCK1 or PCK2 was detected in colon cancer [25], lung cancer [26], melanoma [27], and lymphoma [25], and metastatic breast cancer cells [28]. These findings imply that PCK has non-gluconeogenic function in regulating tumor development.

We recently, for the first time, reported that PCK1 translocates to the ER and acts as a protein kinase phosphorylating Insigs for activating SREBP-dependent lipogenesis and promoting tumor growth [29]. To determine how cancer cells regulate SREBP activation under sterol-sufficient conditions, we treated Huh7 human hepatocellular carcinoma (HCC) cells with the insulin-like growth factor 1 (IGF1), which induces the signaling that is critical for HCC development [30]. Mass spectrometric analyses of immunoprecipitates of Insig1 and Insig2 showed that these proteins bound to PCK1. Cell fractionation analyses revealed that a small portion of PCK1 translocated to the ER upon IGF1 stimulation, and this translocation was blocked by AKT inhibition and elicited by AKT activation. Co-immunoprecipitation analyses of HCC cells and an in vitro GST pull-down assay with purified proteins revealed that AKT bound directly to PCK1. Activated AKT1 in vitro and IGF1-activated AKT in HCC cells phosphorylated PCK1 at evolutionally conserved S90. PCK1 S90A mutant expressed HCC cells were resistant to IGF1- or active AKT1-induced PCK1 S90 phosphorylation and ER translocation. In contrast, the phosphorylation-mimicking PCK1 S90E mutant accumulated in the ER without IGF1 stimulation indicated that AKT1-mediated PCK1 S90 phosphorylation is required and sufficient for the ER translocation of PCK1. Importantly, PCK1 S90 phosphorylation reduced PCK1’s binding affinity to oxaloacetate and its enzymatic activity to produce phosphoenolpyruvate. Thus, AKT-mediated PCK1 phosphorylation inhibited the canonical function of PCK1 in gluconeogenesis and induced and ER translocation. Notably, only AKT-phosphorylated purified wide-type PCK1, but not purified PCK1 S90A, interacted with purified Insig1/2. The expression of Insig1/2 truncation mutants revealed that the Insig1/2 loop 1 bound to PCK1 [29]. These results indicate that PCK1 S90 phosphorylation is required for PCK1’s binding to Insig1/2.

We and other groups previously demonstrated that metabolic enzymes can possess protein kinase activity to phosphorylate a variety of protein substrates for critical regulation of cellular activities [2, 31, 32]. The glycolytic enzyme pyruvate kinase M2 (PKM2) uses PEP as the phosphate donor to phosphorylate histone H3 [2, 33], STAT3 [31], Bub3 [34], myosin light chain 2 (MLC2) [35], AKT1 substrate 1 (AKTIS1) [31], Bcl-2 [31], synapto-associated protein 23 (SNAP-23) [36], and CtBP-interacting protein (CtIP) [37]. Accordingly, PKM2 regulates the Warburg effect, tumor cell migration and metastasis, gene expression, mitosis, and cytokinesis progression, cell proliferation, apoptosis, DNA damage responses, and exosome secretion [2, 31, 36, 38]. The glycolytic enzyme phosphoglycerate kinase 1 (PGK1) uses ATP as a donor and phosphorylates pyruvate dehydrogenase kinase 1 (PDHK1) and Beclin1 to suppress mitochondrial pyruvate metabolism and promote autophagy, respectively [39-41]. Thus, the two ATP-producing glycolytic enzymes can have protein kinase activities. In addition to glycolytic enzymes, we demonstrated that ketohexokinase-A (KHK-A) acts as a protein kinase and uses ATP to phosphorylate phosphoribosyl pyrophosphate synthetase 1 (PRPS1) for promoting the de novo nucleic acid synthesis and HCC formation and p62 for activating Nrf2-dependent antioxidant responses [42, 43]. In line with our previous report that metabolic enzymes could function as protein kinases, we revealed that PCK1 used GTP as the phosphate donor and phosphorylated Insig1 S207 and Insig2 S151 in vitro. This phosphorylation induced by IGF1 was abolished by knock-in expression of PCK1 S90A [29], demonstrating that AKT-phosphorylated PCK1 acts as a protein kinase to phosphorylate Insig1/2.

The significance of PCK1-mediated Insig1/2 phosphorylation was revealed by reduced binding affinity of PCK1-phosphorylated WT Insig1/2 or phospho-mimicking Insig1 S207E and Insig2 S151E, but not their phosphorylation-dead mutants, to [3H] 25-hydroxycholesterol. Consequently, this Insig1/2 phosphorylation resulted in the disruption of Insig-SCAP interaction, SCAP-SREBP1/2 ER-to-Golgi translocation, SREBP1/2 cleavage, nuclear SREBP1/2 accumulation, and SREBP1/2 transcriptional activation. Consequently, this signaling cascade induced expression of SREBP1-targeted fatty acid and triglycerides synthesis genes, including fatty acid synthase (FASN), acetyl-CoA carboxylase-1 (ACCI), stearoyl-CoA desaturase-1 (SCDI), glycerol-3-phosphate acyltransferase (GPAT), and SREBF (encoding SREBP), and SREBP2-mediated transcription of cholesterol biogenesis-related genes, such as HMGCR, HMGC synthesis (HMGCS), low-density lipoprotein receptor (LDLR), and squalene synthase (SS). As expected, PCK1-mediated Insig1/2 phosphorylation increased the incorporation of [14C] glucose into triglycerides and fatty acids. Importantly, this regulation was induced by AKT activation mediated by...
FIGURE 1  PCK1 acting as a protein kinase phosphorylates INSIG1/2, thereby activating SREBP1/2-dependent lipogenesis for tumor development
expression of K-RAS G12V, active IGF1 receptor (IGF1R) V922E mutant, active epidermal growth factor receptor (EGFR) vIII mutant, and platelet-derived growth factor (PDGF) stimulation, which occurred in HCC cells, human melanoma cells, human glioblastoma cells, and human non-small cell lung cancer cells. Thus, PCK1-mediated lipogenesis is a general phenotype in different types of cancer in response to the expression of multiple oncogenes and activation of different receptor tyrosine kinases. In addition, phosphorylation of AKT, PCK1 S90, Insig1 S207, and Insig2 S151 as well as SREBP1 cleavage were dramatically enhanced in normal liver from the mice refed with glucose after fasting, suggesting that blood glucose level in vivo regulates PCK1-mediated Insig1/2 phosphorylation and SREBP1 activation in the liver, revealing a potential mechanism underlying overnutrition-promoted non-alcoholic fatty liver diseases. Notably, phosphorylation of AKT, PCK1 S90, Insig1 S207, and Insig2 S151 as well as SREBP1 cleavage were substantially increased in HCC cells compared with normal human hepatocytes [29], supporting that HCC cells with highly activated AKT have much elevated PCK1-mediated SREBP1 activation.

As expected, knock-in expression of Insig1 S207A/Insig2 S151A or PCK1 S90A inhibited proliferation of HCC cells and active IGF1R V922E or active AKT-induced liver tumor growth in mice. In addition, dominant negative IGF1R L1003R-inhibited tumor growth with reduced PCK1 and Insig1/2 phosphorylation and nuclear SREBP1 accumulation were partially reverted by PCK1 S90D or Insig1 S207D/Insig2 S151D expression, supporting that PCK1-mediated Insig1/2 phosphorylation and subsequent SREBP1 activation promotes HCC development. The clinical relevance of PCK1-regulated SREBP1 activation was demonstrated by analyses of primary HCC and adjacent normal tissue samples, which showed that PCK1 S90 and Insig1 S207/Insig2 S151 phosphorylation and nuclear SREBP1 expression were markedly increased in the HCC specimens and correlated with each other in HCC tumors. Importantly, the levels of PCK1 S90, Insig1 S207/Insig2 S151 phosphorylation, and nuclear SREBP1 expression in HCC samples were inversely correlated with overall survival durations of HCC patients [29].

In summary, we identified PCK1 as a new member of the protein kinome, using GTP, rather than ATP, as a phosphate donor. AKT-mediated PCK1 S90 phosphorylation not only reduced the metabolic activity of PCK1 but also translocated it to the ER, and both regulations reduced its function in gluconeogenesis. Importantly, S90-phosphorylated PCK1 acts as a protein kinase and phosphorylates Insig1/2 thereby reducing oxysterol’s binding to Insig1/2 and activating SREBP1/2-mediated lipogenesis including synthesis of fatty acids, triglycerides, and cholesterol for tumor growth (Figure 1). Thus, our results elucidate an instrumentally integrated regulation between gluconeogenesis and lipogenesis and uncover a critical mechanism by which oncogenic signaling activates SREBP-dependent lipid synthesis in the tumor microenvironment that has normal levels of oxysterol. This finding underscores the significance of the non-canonical function of PCK1 in tumor development and the potential to target the protein kinase activity of PCK1 for cancer treatment.

DECLARATIONS
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT FOR PUBLICATION
Not applicable.

AVAILABILITY OF DATA AND MATERIALS
Not applicable.

COMPETING INTERESTS
The authors declare that they have no competing interests.

FUNDING
Not applicable.

AUTHORS’ CONTRIBUTIONS
Z.L. and D.X. conceived and designed the report. Z.L., D.X., H.J., and L.Z. wrote the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS
Not applicable.

Hongfei Jiang1,∗
Lei Zhu1,∗
Daqian Xu2
Zhimin Lu2

1 The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao, Shandong 266071, P. R. China
2 Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, Institute of Translational Medicine, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310029, P. R. China

Correspondence
Daqian Xu and Zhimin Lu, Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key
Laboratory of Pancreatic Disease, Institute of Translational Medicine, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310029, Zhejiang, P. R. China.

Email: xudaqian@zju.edu.cn; zhiminlu@zju.edu.cn

*These authors contributed equally to this work.

ORCID
Zhimin Lu https://orcid.org/0000-0002-2859-2736

REFERENCES


